Edward Anders Kolb, MD

Hematology/Oncology

Primary Office

Nemours Children's Hospital, Delaware Nemours Children's Hospital, Delaware 1600 Rockland Road Wilmington, DE 19803 Appointment: (800) 416-4441

Other Offices

Get to Know Me

It’s important that the treatment experience is as personal and comfortable as possible for every family. Our department has its own Family Advisory Council whose input helped bring lots of improvements – like room service, refrigerators, prayer groups, better food, and better access to social support. Making life easier for these families is a huge priority for me.

Why I Treat Children

Even sick kids are kids at heart (as I am), just looking for a smile, some fun, a connection with the team members who take care of them. I make it my business to make life better for these kids and their families – as a doctor and through research into promising new drugs.

What I'm Passionate About

I’m a firm believer in clinical trials. In fact, about 80% of our patients are enrolled in clinical trials through the Nemours Center for Cancer and Blood Disorders, and the Nemours Center for Childhood Cancer Research, where I’m director of both. This number is much higher than for adults with cancer, and much higher for children with other kinds of diseases. We also participate in the national Pediatric Preclinical Testing Program, which makes new therapies available for kids sooner. In our department, participating in clinical trials and research studies is the standard of our family-centered care.

Education & Training

Fellowship

  • Pediatric Hematology/Oncology - Memorial Sloan Kettering Cancer Center, 2002

Internship Residency

  • Pediatrics - St. Christophers Hospital for Children, 1999

Medical/Dental School

  • MD - Jefferson Medical College, 1996

Board Certifications

  • American Board of Pediatrics/Pediatric Hematology-Oncology

Awards & Recognition

  • 2021 Lifetime Achievement Honoree, The Leukemia & Lymphoma Society
  • 2016 Philadelphia Magazine's Top Doctors
  • 2014 Best Doctors in America
  • 2014 Delaware Today magazine, Top Doctors
  • 2013 Appointed member of the Scientific Council, Children’s Oncology Group (COG)
  • 2013 Best Doctors in America
  • 2013 Chair, Myeloid Disease Committee, Children’s Oncology Group (COG)
  • 2002 Merit Award, American Society of Clinical Oncology
  • 2012 Resident Educator of the Month
  • 2011 Best Doctors in America
  • 2011 Leukemia & Lymphoma Society, Man of the Year Candidate (Runner-up)
  • 2011 Nemours, Physician Award for Excellence in Scholarship
  • 2010 Nemours Alfred I. duPont Hospital for Children, Physician of the Year
  • 2007 Member, Society for Pediatric Research

Insurance Accepted

  • Aetna Better Health FL Medicaid and Healthy Kids
  • Aetna Better Health PA Kids HMO
  • Aetna HMO
  • Aetna HMO/POS/PPO/EPO
  • Aetna PPO/POS/EPO
  • Amerihealth Caritas DE - PENNSYLVANIA SPECIALISTS ONLY
  • Amerihealth Caritas Delaware
  • AvMed
  • Blue Cross and Blue Shield HMO
  • Blue Cross and Blue Shield Non HMO
  • Blue Cross Blue Shield Florida Blue Select
  • Carefirst MD Community Health Plan Mcaid
  • Cigna & Great West HMO/POS Open Access
  • Cigna & Great West PPO/EPO
  • Cigna/Great West HMO EPO POS
  • Cigna/Great West PPO
  • Community Care Plan Medicaid
  • Delaware First Health
  • Delaware Medicaid/Diamond State
  • Delaware Medicare
  • Devon Health Services
  • Employers Health Network PPO
  • Evolutions Healthcare
  • Fidelis Care NJ Medicaid HMO
  • First Health Aetna PPO/EPO
  • First Health/Affordable PPO
  • Florida Medicaid
  • Geisinger Health Plan Commercial
  • Global Medical Managment DE/PA
  • Health First Health Plans
  • Health Partners Medicaid/Kidz Partner HMO
  • HEALTHSMART HLTH PLANS PPO ORL
  • Highmark Blue Cross Blue Shield of Delaware
  • Highmark Blue Cross Blue Shield of Delaware *PA Loc Contiguous to DE*
  • Highmark Blue Cross Blue Shield of Delaware *PA Loc NONContiguous to DE*
  • Highmark Blue Cross Blue Shield of Pennsylvania
  • Highmark Medicaid Health Options
  • Horizon Blue Cross Blue Shield of New Jersey
  • Humana HMO/POS
  • IBC Amerihealth Keystone HMO/PPO [Delaware Locations]
  • Independance Blue Cross/Amerihealth/Keystone Health Plan
  • Insurance Administrators of America
  • INTEGRA Administrative Group (ClaimsBridge)
  • Interlink Transplant
  • Keystone First Medicaid HMO
  • Lifetrac Transplant
  • Maryland Medicaid
  • Molina Healthcare Medicaid
  • Multiplan PPO
  • New Jersey Medicaid
  • Olympus Managed Healthcare PPO DE/PA
  • Olympus Managed Healthcare PPO ORL
  • Pennsylvania Medicaid
  • Plan Vista/NPPN PPO
  • Preferred Healthcare PPO
  • Private Health Care Systems (PHCS)
  • Qualcare HMO/POS/PPO
  • Seminole Tribe of Florida
  • Simply Healthcare Healthy Kids
  • Simply Healthcare Medicaid HMO
  • Star Healthcare Network
  • Three Rivers Provider Network
  • Tricare/Humana Military Health Services
  • United Healthcare of the Mid-Atlantic
  • UPMC MCAID/CHIP PA DE
  • US Family Health Plan
  • Wellpoint Maryland Medcaid

  • Blood and Bone Marrow Transplantation
  • Blood Disorders
  • Cancer Care
  • Leukemia
  • Lymphoma
  • Neuroblastoma
  • Neutropenia

Research Activities

The children we treat need the most powerful, effective therapies right now – not days, weeks, or months from now. So I’m deeply involved in clinical and translational research, actively seeking to learn as much as possible from each child in our care. Our physicians stay up-to-date on the latest research strategies for kids with cancer, because everything we learn will help others in the future.

The focus of our lab is to identify novel therapies for children with cancer. We recognize the challenges that we face: 1) childhood cancer is a rare and orphan disease; 2) it is difficult to complete clinical trials for rare diseases; 3) drug development is focused on malignancies in adults; 4) we need better treatments for children now. To address all these problems, my lab works with a team of investigators at other institutions around the world to identify those therapies most likely to succeed in children and to prioritize them for clinical development. With more than 60 publications resulting in dozens of clinical trials, we have made great progress. Team science is the model that works. We don’t compete, we cooperate and share.

As a member of the Children’s Oncology Group Scientific Council, Chair of the Myeloid Disease committee, member of the Bone Tumor Committee and member of the Young Investigator Committee, I am in a position to maintain a cutting edge and relevant focus in my lab. We are continually taking results from the bench to bedside and back again; asking those research questions that will have the greatest impact on patient care. Our mission is, simply stated, to find better treatments for childhood cancer. Cure is not impossible with the right teams asking the right questions.

Medical Interests

  • Bone marrow failure systems
  • Graft vs. host disease
  • Retinoblastoma
  • Transplant for inherited disorders
  • Treatment of non-malignant disorders of the bone marrow and immune system

  • Getz, K. D., Alonzo, T. A., Sung, L., Meshinchi, S., Gerbing, R. B., Raimondi, S., & Aplenc, R. (2022). Cytarabine dose reduction in patients with low-risk acute myeloid leukemia: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 69(1). doi:10.1002/pbc.29313

    View Full Publication
  • Lamble, A. J., Eidenschink Brodersen, L., Alonzo, T. A., Wang, J., Pardo, L., Sung, L., & Meshinchi, S. (2022). CD123 Expression Is Associated With High-Risk Disease Characteristics in Childhood Acute Myeloid Leukemia: A Report From the Children's Oncology Group. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 40(3), 252-261. doi:10.1200/JCO.21.01595

    View Full Publication
  • Kutny, M. A., Alonzo, T. A., Abla, O., Rajpurkar, M., Gerbing, R. B., Wang, Y.-C., & Gregory, J., Jr. (2022). Assessment of Arsenic Trioxide and All-trans Retinoic Acid for the Treatment of Pediatric Acute Promyelocytic Leukemia: A Report from the Children's Oncology Group AAML1331 Trial. JAMA Oncology, 8(1), 79-87. doi:10.1001/jamaoncol.2021.5206

    View Full Publication
  • Brivio, E., Baruchel, A., Beishuizen, A., Bourquin, J.-P., Brown, P. A., Cooper, T., & Zwaan, C. M. (2022). Targeted inhibitors and antibody immunotherapies: Novel therapies for paediatric leukaemia and lymphoma. European Journal of Cancer, 164, 1-17. doi:10.1016/j.ejca.2021.12.029

    View Full Publication
  • Elsayed, A. H., Cao, X., Mitra, A. K., Wu, H., Raimondi, S., Cogle, C., & Lamba, J. K. (2022). Polygenic Ara-C Response Score Identifies Pediatric Patients With Acute Myeloid Leukemia in Need of Chemotherapy Augmentation. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 40(7), 772-783. doi:10.1200/JCO.21.01422

    View Full Publication
  • Pommert, L., Cooper, T. M., Gerbing, R. B., Brodersen, L., Loken, M., Gamis, A., & Kolb, E. A. (2022). Blood Count Recovery Following Induction Therapy for Acute Myeloid Leukemia in Children Does Not Predict Survival. Cancers, 14(3). doi:10.3390/cancers14030616

  • Barwe, S. P., Sebastian, A., Sidhu, I., Kolb, E. A., & Gopalakrishnapillai, A. (2022). Modeling Down Syndrome Myeloid Leukemia by Sequential Introduction of GATA1 and STAG2 Mutations in Induced Pluripotent Stem Cells with Trisomy 21. Cells, 11(4). doi:10.3390/cells11040628

    View Full Publication
  • Barwe, S. P., Kisielewski, A., Bonvini, E., Muth, J., Davidson-Moncada, J., Kolb, E. A., & Gopalakrishnapillai, A. (2022). Efficacy of Flotetuzumab in Combination with Cytarabine in Patient-Derived Xenograft Models of Pediatric Acute Myeloid Leukemia. Journal of Clinical Medicine, 11(5). doi:10.3390/jcm11051333

  • Heikamp, E. B., Henrich, J. A., Perner, F., Wong, E. M., Hatton, C., Wen, Y., & Armstrong, S. A. (2022). The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML. Blood, 139(6), 894-906. doi:10.1182/blood.2021012806

    View Full Publication
  • Getz, K. D., Alonzo, T. A., Sung, L., Meshinchi, S., Gerbing, R. B., Raimondi, S., & Aplenc, R. (2022). Cytarabine dose reduction in patients with low-risk acute myeloid leukemia: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 69(1). doi:10.1002/pbc.29313

    View Full Publication
  • Hecht, A., Meyer, J. A., Behnert, A., Wong, E., Chehab, F., Olshen, A., & Stieglitz, E. (2022). Molecular and phenotypic diversity of CBL-mutated juvenile myelomonocytic leukemia. Haematologica, 107(1), 178-186. doi:10.3324/haematol.2020.270595

    View Full Publication
  • Hecht, A., Meyer, J. A., Behnert, A., Wong, E., Chehab, F., Olshen, A., & Stieglitz, E. (2022). Molecular and phenotypic diversity of CBL-mutated juvenile myelomonocytic leukemia. Haematologica, 107(1), 178-186. doi:10.3324/haematol.2020.270595

    View Full Publication
  • Kutny, M. A., Alonzo, T. A., Abla, O., Rajpurkar, M., Gerbing, R. B., Wang, Y.-C., & Gregory, J., Jr. (2022). Assessment of Arsenic Trioxide and All-trans Retinoic Acid for the Treatment of Pediatric Acute Promyelocytic Leukemia: A Report from the Children's Oncology Group AAML1331 Trial. JAMA Oncology, 8(1), 79-87. doi:10.1001/jamaoncol.2021.5206

    View Full Publication
  • Dandoy, C. E., Davies, S. M., Ahn, K. W., He, Y., Kolb, A. E., Levine, J., & Eapen, M. (2021). Comparison of total body irradiation versus non-total body irradiation containing regimens for de novo acute myeloid leukemia in children. Haematologica, 106(7), 1839-1845. doi:10.3324/haematol.2020.249458

    View Full Publication
  • Kendsersky, N. M., Lindsay, J., Anders Kolb, E., Smith, M. A., Teicher, B. A., Erickson, S. W., & Maris, J. M. (2021). The B7-H3-targeting antibody-Drug conjugate m276-SL-PBD is potently effective against pediatric cancer preclinical solid tumor models. Clinical Cancer Research, 27(10), 2938-2946. doi:10.1158/1078-0432.CCR-20-4221

    View Full Publication
  • van Dijk, A. D., Hoff, F. W., Qiu, Y., Gerbing, R. B., Gamis, A. S., Aplenc, R., & Horton, T. M. (2021). Bortezomib is significantly beneficial for de novo pediatric AML patients with low phosphorylation of the NF-KB subunit RelA. Proteomics - Clinical Applications. doi:10.1002/prca.202100072

  • Kutny, M. A., Alonzo, T. A., Abla, O., Rajpurkar, M., Gerbing, R. B., Wang, Y.-C., & Gregory, J., Jr. (2022). Assessment of Arsenic Trioxide and All-trans Retinoic Acid for the Treatment of Pediatric Acute Promyelocytic Leukemia: A Report from the Children's Oncology Group AAML1331 Trial. JAMA Oncology, 8(1), 79-87. doi:10.1001/jamaoncol.2021.5206

  • Smith, S. M., Zhang, S., Sundaram, V., Roth, M., Andolina, J. R., Schapira, L., & Chaudhury, S. (2021). Physician risk perceptions and surveillance practices for tyrosine kinase inhibitor long-term effects in pediatric CML. Pediatric Hematology and Oncology. doi:10.1080/08880018.2021.2017085

  • Rasche, M., Steidel, E., Zimmermann, M., Bourquin, J.-P., Boztug, H., Janotova, I., & Reinhardt, D. (2021). Second relapse of pediatric patients with acute myeloid leukemia: A report on current treatment strategies and outcome of the AML-BFM study group. Cancers, 13(4), 1-14. doi:10.3390/cancers13040789

  • Hingorani, P., Roth, M. E., Wang, Y., Zhang, W., Gill, J. B., Harrison, D. J., & Gorlick, R. (2021). ABBV-085, antibody-drug conjugate targeting LRRC15, is effective in osteosarcoma: A report by the pediatric preclinical testing consortium. Molecular Cancer Therapeutics, 20(3), 535-540. doi:10.1158/1535-7163.MCT-20-0406

    View Full Publication
  • Rasche, M., Zimmermann, M., Steidel, E., Alonzo, T., Aplenc, R., Bourquin, J.-P., & Reinhardt, D. (2021). Survival following relapse in children with acute myeloid leukemia: A report from aml-bfm and cog. Cancers, 13(10). doi:10.3390/cancers13102336

  • Kaeding, A. J., Barwe, S. P., Gopalakrishnapillai, A., Ries, R. E., Alonzo, T. A., Gerbing, R. B., & Meshinchi, S. (2021). Mesothelin is a novel cell surface disease marker and potential therapeutic target in acute myeloid leukemia. Blood Advances, 5(9), 2350-2361. doi:10.1182/BLOODADVANCES.2021004424

    View Full Publication
  • O'Brien, M. M., Alonzo, T. A., Cooper, T. M., Levine, J. E., Brown, P. A., Slone, T., & Kolb, E. A. (2021). Results of a phase 2, multicenter, single-arm, open-label study of lenalidomide in pediatric patients with relapsed or refractory acute myeloid leukemia. Pediatric Blood and Cancer, 68(7). doi:10.1002/pbc.28946

    View Full Publication
  • Plana, A., Furner, B., Palese, M., Dussault, N., Birz, S., Graglia, L., & Volchenboum, S. L. (2021). Pediatric Cancer Data Commons: Federating and Democratizing Data for Childhood Cancer Research. JCO clinical cancer informatics, 5, 1034-1043. doi:10.1200/CCI.21.00075

    View Full Publication
  • Sidhu, I., Barwe, S. P., Kiick, K. L., Kolb, E. A., & Gopalakrishnapillai, A. (2021). A 3-D hydrogel based system for hematopoietic differentiation and its use in modeling down syndrome associated transient myeloproliferative disorder. Biomaterials Science, 9(18), 6266-6281. doi:10.1039/d1bm00442e

    View Full Publication
  • Tarlock, K., Lamble, A. J., Wang, Y.-C., Gerbing, R. B., Ries, R. E., Loken, M. R., & Meshinchi, S. (2021). CEBPA-bZip mutations are associated with favorable prognosis in de novo AML: a report from the Children's Oncology Group. Blood, 138(13), 1137-1147. doi:10.1182/blood.2020009652

    View Full Publication
  • Pollard, J. A., Guest, E., Alonzo, T. A., Gerbing, R. B., Loken, M. R., Brodersen, L. E., & Gamis, A. S. (2021). Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric KMT2A-Rearranged AML: Results From the Phase III Children's Oncology Group Trial AAML0531. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 39(28), 3149-3160. doi:10.1200/JCO.20.03048

    View Full Publication
  • Elgarten, C. W., Wood, A. C., Li, Y., Alonzo, T. A., Brodersen, L. E., Gerbing, R. B., & Aplenc, R. (2021). Outcomes of intensification of induction chemotherapy for children with high-risk acute myeloid leukemia: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 68(12). doi:10.1002/pbc.29281

    View Full Publication
  • Gopalakrishnapillai, A., Correnti, C. E., Pilat, K., Lin, I., Chan, M. K., Bandaranayake, A. D., & Barwe, S. P. (2021). Immunotherapeutic targeting of mesothelin positive pediatric aml using bispecific t cell engaging antibodies. Cancers, 13(23). doi:10.3390/cancers13235964

  • Hitzler, J., Alonzo, T., Gerbing, R., Beckman, A., Hirsch, B., Raimondi, S., & Berman, J. N. (2021). High-dose AraC is essential for the treatment of ML-DS independent of postinduction MRD: results of the COG AAML1531 trial. Blood, 138(23), 2337-2346. doi:10.1182/blood.2021012206

    View Full Publication
  • Huang, B. J., Smith, J. L., Wang, Y.-C., Taghizadeh, K., Leonti, A. R., Ries, R. E., & Meshinchi, S. (2021). CBFB-MYH11 fusion transcripts distinguish acute myeloid leukemias with distinct molecular landscapes and outcomes. Blood Advances, 5(23), 4963-4968. doi:10.1182/bloodadvances.2021004965

    View Full Publication
  • Kutny, M. A., Alonzo, T. A., Abla, O., Rajpurkar, M., Gerbing, R. B., Wang, Y.-C., & Gregory, J., Jr. (2022). Assessment of Arsenic Trioxide and All-trans Retinoic Acid for the Treatment of Pediatric Acute Promyelocytic Leukemia: A Report from the Children's Oncology Group AAML1331 Trial. JAMA Oncology, 8(1), 79-87. doi:10.1001/jamaoncol.2021.5206

  • Hecht, A., Meyer, J. A., Behnert, A., Wong, E., Chehab, F., Olshen, A., & Stieglitz, E. (2022). Molecular and phenotypic diversity of CBL-mutated juvenile myelomonocytic leukemia. Haematologica, 107(1), 178-186. doi:10.3324/haematol.2020.270595

    View Full Publication
  • Nevil, G., Roth, M., Gill, J., Zhang, W., Teicher, B., Erickson, S. W., & Gorlick, R. (2020). Initial in vivo testing of TPO-receptor agonist eltrombopag in osteosarcoma patient-derived xenograft models by the pediatric preclinical testing consortium. Pediatric Hematology and Oncology, 38(1), 8-13. doi:10.1080/08880018.2020.1802539

    View Full Publication
  • Kinnaman, Hamill, D., Yabe, M., Powell, J., Benhamida, J., Hasselblatt, M., & Shukla, N. (2020). Aggressive hematopoietic malignancy characterized by biallelic loss of SMARCB1. JCO Precision Oncology, 4, 1280-1284. doi:10.1200/PO.20.00215

  • Miller, R., Coyne, E., Crowgey, E. L., Eckrich, D., Myers, J. C., Villanueva, R., & Kolb, E. A. (2020). Implementation of a learning healthcare system for sickle cell disease. JAMIA Open, 3(3), 349-359. doi:10.1093/JAMIAOPEN/OOAA024

  • Kazak, A. E., Chen, F. F., Hwang, W.-T., Askins, M. A., Vega, G., Kolb, E. A., & Barakat, L. P. (2020). Stability and change in family psychosocial risk over 6 months in pediatric cancer and its association with medical and psychosocial healthcare utilization. Pediatric Blood and Cancer, 67(2). doi:10.1002/pbc.28051

    View Full Publication
  • Smith, J. L., Ries, R. E., Hylkema, T., Alonzo, T. A., Gerbing, R. B., Santaguida, M. T., & Meshinchi, S. (2020). Comprehensive transcriptome profiling of cryptic CBFA2T3-GLIS2 fusion-positive AML defines novel therapeutic options: A COG and target pediatric AML study. Clinical Cancer Research, 26(3), 726-737. doi:10.1158/1078-0432.CCR-19-1800

    View Full Publication
  • Barwe, S. P., Gopalakrisnapillai, A., Mahajan, N., Druley, T. E., Kolb, E. A., & Crowgey, E. L. (2020). Strong concordance between RNA structural and single nucleotide variants identified via next generation sequencing techniques in primary pediatric leukemia and patient-derived xenograft samples. Genomics and Informatics, 18(1). doi:10.5808/GI.2020.18.1.e6

  • Crowgey, E. L., Mahajan, N., Wong, W. H., Gopalakrishnapillai, A., Barwe, S. P., Kolb, E. A., & Druley, T. E. (2020). Error-corrected sequencing strategies enable comprehensive detection of leukemic mutations relevant for diagnosis and minimal residual disease monitoring. BMC Medical Genomics, 13(1). doi:10.1186/s12920-020-0671-8

    View Full Publication
  • Davies, S. M., Iannone, R., Alonzo, T. A., Wang, Y.-C., Gerbing, R., Soni, S., & Leung, W. (2020). A Phase 2 Trial of KIR-Mismatched Unrelated Donor Transplantation Using in Vivo T Cell Depletion with Antithymocyte Globulin in Acute Myelogenous Leukemia: Children's Oncology Group AAML05P1 Study. Biology of Blood and Marrow Transplantation, 26(4), 712-717. doi:10.1016/j.bbmt.2019.12.723

    View Full Publication
  • Kolb, E. A., Houghton, P. J., Kurmasheva, R. T., Mosse, Y. P., Maris, J. M., Erickson, S. W., & Gorlick, R. (2020). Preclinical evaluation of the combination of AZD1775 and irinotecan against selected pediatric solid tumors: A Pediatric Preclinical Testing Consortium report. Pediatric Blood and Cancer, 67(5). doi:10.1002/pbc.28098

    View Full Publication
  • Cooper, T. M., Absalon, M. J., Alonzo, T. A., Gerbing, R. B., Leger, K. J., Hirsch, B. A., & Kolb, E. A. (2020). Phase I/II study of CPX-351 followed by fludarabine, cytarabine, and granulocyte-colony stimulating factor for children with relapsed acute myeloid leukemia: A report from the children's oncology group. Journal of Clinical Oncology, 38(19), 2170-2177. doi:10.1200/JCO.19.03306

    View Full Publication
  • Harrison, D. J., Gill, J. D., Roth, M. E., Zhang, W., Teicher, B., Erickson, S., & Gorlick, R. (2020). Initial in vivo testing of a multitarget kinase inhibitor, regorafenib, by the Pediatric Preclinical Testing Consortium. Pediatric Blood and Cancer, 67(6). doi:10.1002/pbc.28222

    View Full Publication
  • Aplenc, R., Meshinchi, S., Sung, L., Alonzo, T., Choi, J., Fisher, B., & Gamis, A. (2020). Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children's Oncology Group. Haematologica, 105(7), 1879-1886. doi:10.3324/haematol.2019.220962

    View Full Publication
  • Getz, K. D., Sung, L., Alonzo, T. A., Leger, K. J., Gerbing, R. B., Pollard, J. A., & Aplenc, R. (2020). Effect of dexrazoxane on left ventricular systolic function and treatment outcomes in patients with acute myeloid leukemia: A report from the Children's oncology group. Journal of Clinical Oncology, 38(21), 2398-2406. doi:10.1200/JCO.19.02856

    View Full Publication
  • Pearson, A. D. J., Zwaan, C. M., Kolb, E. A., Karres, D., Guillot, J., Kim, S. Y., & Vassal, G. (2020). Paediatric Strategy Forum for medicinal product development for acute myeloid leukaemia in children and adolescents: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. European Journal of Cancer, 136, 116-129. doi:10.1016/j.ejca.2020.04.038

    View Full Publication
  • Quagliano, A., Gopalakrishnapillai, A., Anders Kolb, E., & Barwe, S. P. (2020). CD81 knockout promotes chemosensitivity and disrupts in vivo homing and engraftment in acute lymphoblastic leukemia. Blood Advances, 4(18), 4393-4405. doi:10.1182/BLOODADVANCES.2020001592

    View Full Publication
  • Gill, J., Zhang, W., Zhang, Z., Roth, M., Harrison, D. J., Rowshan, S., & Gorlick, R. (2020). Dose-response effect of eribulin in preclinical models of osteosarcoma by the pediatric preclinical testing consortium. Pediatric Blood and Cancer, 67(10). doi:10.1002/pbc.28606

    View Full Publication
  • Brodersen, L. E., Gerbing, R. B., Pardo, M. L., Alonzo, T. A., Paine, D., Fritschle, W., & Loken, M. R. (2020). Morphologic remission status is limited compared to DN flow cytometry: a Children's Oncology Group AAML0531 report. Blood Advances, 4(20), 5050-5061. doi:10.1182/BLOODADVANCES.2020002070

    View Full Publication
  • Barwe, S. P., Sidhu, I., Kolb, E. A., & Gopalakrishnapillai, A. (2020). Modeling Transient Abnormal Myelopoiesis Using Induced Pluripotent Stem Cells and CRISPR/Cas9 Technology. Molecular Therapy - Methods and Clinical Development, 19, 201-209. doi:10.1016/j.omtm.2020.09.007

  • Hecht, A., Meyer, J. A., Behnert, A., Wong, E., Chehab, F., Olshen, A., & Stieglitz, E. (2022). Molecular and phenotypic diversity of CBL-mutated juvenile myelomonocytic leukemia. Haematologica, 107(1), 178-186. doi:10.3324/haematol.2020.270595

    View Full Publication
  • Currier, A. W., Kolb, E. A., Gorlick, R. G., Roth, M. E., Gopalakrishnan, V., & Sampson, V. B. (2019). p27/Kip1 functions as a tumor suppressor and oncoprotein in osteosarcoma. Scientific Reports, 9(1). doi:10.1038/s41598-019-42450-0

    View Full Publication
  • Rokita, J. L., Rathi, K. S., Cardenas, M. F., Upton, K. A., Jayaseelan, J., Cross, K. L., & Maris, J. M. (2019). Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design. Cell Reports, 29(6), 1675-1689.e9. doi:10.1016/j.celrep.2019.09.071

    View Full Publication
  • Athale, U., Hijiya, N., Patterson, B. C., Bergsagel, J., Andolina, J. R., Bittencourt, H., & Johnston, D. L. (2019). Management of chronic myeloid leukemia in children and adolescents: Recommendations from the Children's Oncology Group CML Working Group. Pediatric Blood and Cancer, 66(9). doi:10.1002/pbc.27827

    View Full Publication
  • Murphy, B. R., Roth, M., Kolb, E. A., Alonzo, T., Gerbing, R., & Wells, R. J. (2019). Development of acute lymphoblastic leukemia following treatment for acute myeloid leukemia in children with Down syndrome: A case report and retrospective review of Children's Oncology Group acute myeloid leukemia trials. Pediatric Blood and Cancer, 66(8). doi:10.1002/pbc.27700

    View Full Publication
  • McNeer, N. A., Philip, J., Geiger, H., Ries, R. E., Lavallee, V.-P., Walsh, M., & Kentsis, A. (2019). Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemia. Leukemia, 33(8), 1934-1943. doi:10.1038/s41375-019-0402-3

    View Full Publication
  • Crowgey, E. L., Washburn, M. C., Kolb, E. A., & Puffenberger, E. G. (2019). Development of a Novel Next-Generation Sequencing Assay for Carrier Screening in Old Order Amish and Mennonite Populations of Pennsylvania. Journal of Molecular Diagnostics, 21(4), 687-694. doi:10.1016/j.jmoldx.2019.03.004

    View Full Publication
  • Pai, A. L. H., Swain, A. M., Chen, F. F., Hwang, W.-T., Vega, G., Carlson, O., & Kazak, A. E. (2019). Screening for Family Psychosocial Risk in Pediatric Hematopoietic Stem Cell Transplantation with the Psychosocial Assessment Tool. Biology of Blood and Marrow Transplantation, 25(7), 1374-1381. doi:10.1016/j.bbmt.2019.03.012

    View Full Publication
  • Lowery, C. D., Dowless, M., Renschler, M., Blosser, W., VanWye, A. B., Stephens, J. R., & Stancato, L. F. (2019). Broad spectrum activity of the checkpoint kinase 1 inhibitor prexasertib as a single agent or chemopotentiator across a range of preclinical pediatric tumor models. Clinical Cancer Research, 25(7), 2278-2289. doi:10.1158/1078-0432.CCR-18-2728

    View Full Publication
  • Dupuis, L. L., Tamura, R. N., Kelly, K. M., Krischer, J. P., Langevin, A.-M., Chen, L., & McLean, T. W. (2019). Risk factors for chemotherapy-induced nausea in pediatric patients receiving highly emetogenic chemotherapy. Pediatric Blood and Cancer, 66(4). doi:10.1002/pbc.27584

    View Full Publication
  • Bolouri, H., Farrar, J. E., Triche, T., Jr, Ries, R. E., Lim, E. L., Alonzo, T. A., & Meshinchi, S. (2019). Publisher Correction: The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions (Nature Medicine, (2017), 24, 1, (103-112), 10.1038/nm.4439). Nature Medicine, 25(3), 530. doi:10.1038/s41591-019-0369-7

    View Full Publication
  • Davidow, K. A., Walter, A. W., & Kolb, E. A. (2019). Bone marrow transplant and pediatric multiple myeloma. Pediatric Blood and Cancer, 66(2). doi:10.1002/pbc.27528

    View Full Publication
  • Isakoff, M. S., Goldsby, R., Villaluna, D., Krailo, Hingorani, P., Collier, A., & Janeway, K. A. (2019). A phase II study of eribulin in recurrent or refractory osteosarcoma: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 66(2). doi:10.1002/pbc.27524

    View Full Publication
  • Esbenshade, A. J., Kahalley, L. S., Baertschiger, R., Dasgupta, R., Goldsmith, K. C., Nathan, P. C., & Dhall, G. (2019). Mentors' perspectives on the successes and challenges of mentoring in the COG Young Investigator mentorship program: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 66(10). doi:10.1002/pbc.27920

    View Full Publication
  • Kazak, A. E., Swain, A. M., Canter, K., Vega, G., Joffe, N., Deatrick, J. A., & Pai, A. L. H. (2019). A psychosocial clinical care pathway for pediatric hematopoietic stem cell transplantation. Pediatric Blood and Cancer, 66(10). doi:10.1002/pbc.27889

    View Full Publication
  • Tarlock, K., Zhong, S., He, Y., Ries, R., Severson, E., Bailey, M., & He, J. (2018). Distinct age-associated molecular profiles in acute myeloid leukemia defined by comprehensive clinical genomic profiling. Oncotarget, 9(41), 26417-26430. doi:10.18632/oncotarget.25443

  • Dupuis, L. L., Kelly, K. M., Krischer, J. P., Langevin, A.-M., Tamura, R. N., Xu, P., & McLean, T. W. (2018). Acupressure bands do not improve chemotherapy-induced nausea control in pediatric patients receiving highly emetogenic chemotherapy: A single-blinded, randomized controlled trial. Cancer, 124(6), 1188-1196. doi:10.1002/cncr.31198

    View Full Publication
  • Scialla, M. A., Canter, K. S., Chen, F. F., Kolb, E. A., Sandler, E., Wiener, L., & Kazak, A. E. (2018). Delivery of care consistent with the psychosocial standards in pediatric cancer: Current practices in the United States. Pediatric Blood and Cancer, 65(3). doi:10.1002/pbc.26869

    View Full Publication
  • Mills, C. C., Kolb, E. A., & Sampson, V. B. (2018). Development of chemotherapy with cell-cycle inhibitors for adult and pediatric cancer therapy. Cancer Research, 78(2), 320-325. doi:10.1158/0008-5472.CAN-17-2782

    View Full Publication
  • Bolouri, H., Farrar, J. E., Triche, T., Ries, R. E., Lim, E. L., Alonzo, T. A., & Meshinchi, S. (2018). The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions. Nature Medicine, 24(1), 103-112. doi:10.1038/nm.4439

    View Full Publication
  • Mills, C. C., Kolb, E. A., & Sampson, V. B. (2017). Recent advances of cell-cycle inhibitor therapies for pediatric cancer. Cancer Research, 77(23), 6489-6498. doi:10.1158/0008-5472.CAN-17-2066

    View Full Publication
  • Scialla, M. A., Canter, K. S., Chen, F. F., Kolb, E. A., Sandler, E., Wiener, L., & Kazak, A. E. (2017). Implementing the psychosocial standards in pediatric cancer: Current staffing and services available. Pediatric Blood and Cancer, 64(11). doi:10.1002/pbc.26634

    View Full Publication
  • Alexander, T. B., Bhakta, N., Kolb, E. A., & Rubnitz, J. E. (2017). Opportunities for expanding clinical trial enrollment for relapsed and refractory pediatric acute myeloid leukemia in the United States and Canada. Pediatric Blood and Cancer, 64(11). doi:10.1002/pbc.26632

    View Full Publication
  • Tarlock, K., Alonzo, T. A., Loken, M. R., Gerbing, R. B., Ries, R. E., Aplenc, R., & Meshinchi, S. (2017). Disease characteristics and prognostic implications of cell-surface FLT3 receptor (CD135) expression in pediatric acute myeloid leukemia: A report from the Children's Oncology Group. Clinical Cancer Research, 23(14), 3649-3656. doi:10.1158/1078-0432.CCR-16-2353

    View Full Publication
  • Vetter, N. S., Kolb, E. A., Mills, C. C., & Sampson, V. B. (2017). The microtubule network and cell death are regulated by an miR-34a/stathmin 1/BIIITubulin axis. Molecular Cancer Research, 15(7), 953-964. doi:10.1158/1541-7786.MCR-16-0372

    View Full Publication
  • Gopalakrishnapillai, A., Kolb, E. A., McCahan, S. M., & Barwe, S. P. (2017). Epigenetic drug combination induces remission in mouse xenograft models of pediatric acute myeloid leukemia. Leukemia Research, 58, 91-97. doi:10.1016/j.leukres.2017.05.004

    View Full Publication
  • Tomizawa, D., & Kolb, E. A. (2017). Down syndrome and AML: Where do we go from here? Blood, 129(25), 3274-3275. doi:10.1182/blood-2017-04-780031

    View Full Publication
  • Bloh, K. M., Bialk, P. A., Gopalakrishnapillai, A., Kolb, E. A., & Kmiec, E. B. (2017). CRISPR/Cas9-Directed Reassignment of the GATA1 Initiation Codon in K562 Cells to Recapitulate AML in Down Syndrome. Molecular Therapy - Nucleic Acids, 7, 288-298. doi:10.1016/j.omtn.2017.04.009

  • Cartledge, D. M., Robbins, K. M., Drake, K. M., Sternberg, R., Stabley, D. L., Gripp, K. W., & Napper, A. D. (2017). Cytotoxicity of zardaverine in embryonal rhabdomyosarcoma from a Costello syndrome patient. Frontiers in Oncology, 7(APR). doi:10.3389/fonc.2017.00042

  • Kurmasheva, R. T., Gorlick, R., Kolb, E. A., Keir, S. T., Maris, J. M., Lock, R. B., & Smith, M. A. (2017). Initial testing of VS-4718, a novel inhibitor of focal adhesion kinase (FAK), against pediatric tumor models by the Pediatric Preclinical Testing Program. Pediatric Blood and Cancer, 64(4). doi:10.1002/pbc.26304

    View Full Publication
  • Lock, R., Carol, H., Maris, J. M., Kolb, E. A., Gorlick, R., Reynolds, C. P., & Smith, M. A. (2017). Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program. Pediatric Blood and Cancer, 64(4). doi:10.1002/pbc.26263

    View Full Publication
  • Murphy, B., Yin, H., Maris, J. M., Kolb, E. A., Gorlick, R., Reynolds, C. P., & Houghton, P. J. (2016). Evaluation of alternative in vivo drug screening methodology: A single mouse analysis. Cancer Research, 76(19), 5798-5809. doi:10.1158/0008-5472.CAN-16-0122

    View Full Publication
  • Kang, M. H., Reynolds, C. P., Kolb, E. A., Gorlick, R., Carol, H., Lock, R., & Smith, M. A. (2016). Initial Testing (Stage 1) of MK-8242: A Novel MDM2 Inhibitor: by the Pediatric Preclinical Testing Program. Pediatric Blood and Cancer, 63(10), 1744-1752. doi:10.1002/pbc.26064

    View Full Publication
  • Gopalakrishnapillai, A., Kolb, E. A., Dhanan, P., Bojja, A. S., Mason, R. W., Corao, D., & Barwe, S. P. (2016). Generation of pediatric leukemia xenograft models in NSG-B2m mice: Comparison with NOD/SCID mice. Frontiers in Oncology, 6(JUN). doi:10.3389/fonc.2016.00162

  • Maxson, J. E., Ries, R. E., Wang, Y.-C., Gerbing, R. B., Kolb, E. A., Thompson, S. L., & Meshinchi, S. (2016). CSF3R mutations have a high degree of overlap with CEBPA mutations in pediatric AML. Blood, 127(24), 3094-3098. doi:10.1182/blood-2016-04-709899

    View Full Publication
  • Attiyeh, E. F., Maris, J. M., Lock, R., Reynolds, C. P., Kang, M. H., Carol, H., & Smith, M. A. (2016). Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program. Pediatric Blood and Cancer, 63(2), 276-286. doi:10.1002/pbc.25727

    View Full Publication
  • Sampson, V. B., Vetter, N. S., Zhang, W., Patil, P. U., Mason, R. W., George, E., & Kolb, E. A. (2016). Integrating mechanisms of response and resistance against the tubulin binding agent Eribulin in preclinical models of osteosarcoma. Oncotarget, 7(52), 86594-86607. doi:10.18632/oncotarget.13358

    View Full Publication
  • Roth, M., Barris, D. M., Piperdi, S., Kuo, V., Everts, S., Geller, D., & Gorlick, R. (2016). Targeting Glycoprotein NMB With Antibody-Drug Conjugate, Glembatumumab Vedotin, for the Treatment of Osteosarcoma. Pediatric Blood and Cancer, 63(1), 32-38. doi:10.1002/pbc.25688

    View Full Publication
  • Caywood, E. H., & Kolb, E. A. (2015). Challenges in converting Acute Myeloid Leukemia (AML) genomics into AML clinical trials. Journal of Clinical Oncology, 33(36), 4238-4239. doi:10.1200/JCO.2015.63.9252

    View Full Publication
  • Kolb, E. A., & Meshinchi, S. (2015). Acute myeloid leukemia in children and adolescents: Identification of new molecular targets brings promise of new therapies. Hematology (United States), 2015(1), 507-513. doi:10.1182/asheducation-2015.1.507

    View Full Publication
  • Reynolds, C. P., Kang, M. H., Maris, J. M., Kolb, E. A., Gorlick, R., Wu, J., & Smith, M. A. (2015). Initial testing (stage 1) of the anti-microtubule agents cabazitaxel and docetaxel, by the pediatric preclinical testing program. Pediatric Blood and Cancer, 62(11), 1897-1905. doi:10.1002/pbc.25611

    View Full Publication
  • Gopalakrishnapillai, A., Kolb, E. A., Dhanan, P., Mason, R. W., Napper, A., & Barwe, S. P. (2015). Disruption of Annexin II /p11 interaction suppresses leukemia cell binding, homing and engraftment, and sensitizes the leukemia cells to chemotherapy. PLoS ONE, 10(10). doi:10.1371/journal.pone.0140564

    View Full Publication
  • Zwaan, C. M., Kolb, E. A., Reinhardt, D., Abrahamsson, J., Adachi, S., Aplenc, R., & Kaspers, G. J. L. (2015). Collaborative efforts driving progress in pediatric acute myeloid leukemia. Journal of Clinical Oncology, 33(27), 2949-2962. doi:10.1200/JCO.2015.62.8289

    View Full Publication
  • Sampson, V. B., Yoo, S., Kumar, A., Vetter, N. S., & Kolb, E. A. (2015). MicroRNAs and Potential Targets in Osteosarcoma: Review. Frontiers in Pediatrics, 3. doi:10.3389/fped.2015.00069

  • Houghton, P. J., Kurmasheva, R. T., Kolb, E. A., Gorlick, R., Maris, J. M., Wu, J., & Smith, M. A. (2015). Initial testing (stage 1) of the tubulin binding agent nanoparticle albumin-bound (nab) paclitaxel (Abraxane(R)) by the Pediatric Preclinical Testing Program (PPTP). Pediatric Blood and Cancer, 62(7), 1214-1221. doi:10.1002/pbc.25474

    View Full Publication
  • Kolb, E. A., Gorlick, R., Keir, S. T., Maris, J. M., Kang, M. H., Reynolds, C. P., & Smith, M. A. (2015). Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program. Pediatric Blood and Cancer, 62(6), 1106-1109. doi:10.1002/pbc.25329

    View Full Publication
  • Kolb, E. A., Sampson, V., Stabley, D., Walter, A., Sol-Church, K., Cripe, T., & Blaney, S. M. (2015). A phase I trial and viral clearance study of reovirus (Reolysin) in children with relapsed or refractory extra-cranial solid tumors: A Children's Oncology Group Phase I Consortium report. Pediatric Blood and Cancer, 62(5), 751-758. doi:10.1002/pbc.25464

    View Full Publication
  • Smith, M. A., Reynolds, C. P., Kang, M. H., Kolb, E. A., Gorlick, R., Carol, H., & Houghton, P. J. (2015). Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric Cancer Models in the Pediatric Preclinical Testing Program. Clinical Cancer Research, 21(4), 819-832. doi:10.1158/1078-0432.CCR-14-2572

    View Full Publication
  • Smith, M. A., Hampton, O. A., Reynolds, C. P., Kang, M. H., Maris, J. M., Gorlick, R., & Houghton, P. J. (2015). Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673. Pediatric Blood and Cancer, 62(1), 91-98. doi:10.1002/pbc.25201

    View Full Publication

  • English